Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 736

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

Open access
Turner, R. Scott, Thomas, Ronald G., Craft, Suzanne, van Dyck, Christopher H., Mintzer, Jacobo, Reynolds, Brigid A., Brewer, James B., Rissman, Robert A., Raman, Rema, Aisen, Paul S., For the Alzheimer's Disease Cooperative Study, Alzheimer's Disease Cooperative Study, Mintzer, J., Reynolds, B.A., Karlawish, J., Galasko, D., Heidebrink, J., Aggarwal, N., Graff-Radford, N., Sano, M., Petersen, R., Bell, K., Doody, R., Smith, A., Bernick, C., Porteinsson, A., Tariot, P., Mulnard, R., Lerner, A., Schneider, L., Burns, J., Raskind, M., Ferris, S., Jicha, G., Quiceno, M., Obisesan, T., Rosenberg, P., Weintraub, D., Kieburtz, K., Miller, B., Kryscio, R., Alexopoulis, G.·2015·Neurology

Abstract

OBJECTIVE: A randomized, placebo-controlled, double-blind, multicenter 52-week phase 2 trial of resveratrol in individuals with mild to moderate Alzheimer disease (AD) examined its safety and tolerability and effects on biomarker (plasma Aβ40 and Aβ42, CSF Aβ40, Aβ42, tau, and phospho-tau 181) and volumetric MRI outcomes (primary outcomes) and clinical outcomes (secondary outcomes). METHODS: Participants (n = 119) were randomized to placebo or resveratrol 500 mg orally once daily (with dose escalation by 500-mg increments every 13 weeks, ending with 1,000 mg twice daily). Brain MRI and CSF collection were performed at baseline and after completion of treatment. Detailed pharmacokinetics were performed on a subset (n = 15) at baseline and weeks 13, 26, 39, and 52. RESULTS: Resveratrol and its major metabolites were measurable in plasma and CSF. The most common adverse events were nausea, diarrhea, and weight loss. CSF Aβ40 and plasma Aβ40 levels declined more in the placebo group than the resveratrol-treated group, resulting in a significant difference at week 52. Brain volume loss was increased by resveratrol treatment compared to placebo. CONCLUSIONS: Resveratrol was safe and well-tolerated. Resveratrol and its major metabolites penetrated the blood-brain barrier to have CNS effects. Further studies are required to interpret the biomarker changes associated with resveratrol treatment. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with AD resveratrol is safe, well-tolerated, and alters some AD biomarker trajectories. The study is rated Class II because more than 2 primary outcomes were designated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000002035

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 45 references

Cited by

See all 736

Metadata

Authors
Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H., Mintzer, J., Reynolds, B. A., Brewer, J. B., Rissman, R. A., Raman, R., Aisen, P. S., Study, F. T. A. D. C., Study, A. D. C., Mintzer, J., Reynolds, B. A., Karlawish, J., Galasko, D., Heidebrink, J., Aggarwal, N., Graff-Radford, N., Sano, M., Petersen, R., Bell, K., Doody, R., Smith, A., Bernick, C., Porteinsson, A., Tariot, P., Mulnard, R., Lerner, A., Schneider, L., Burns, J., Raskind, M., Ferris, S., Jicha, G., Quiceno, M., Obisesan, T., Rosenberg, P., Weintraub, D., Kieburtz, K., Miller, B., Kryscio, R., & Alexopoulis, G.
Venue
Neurology
Published
2015-10-20
Volume
85
Issue
16
Pages
1383-1391
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W1886477676
Cited by
736
References
45
FWCI
35.73
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000002035
The paper
Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H., Mintzer, J., Reynolds, B. A., Brewer, J. B., Rissman, R. A., Raman, R., Aisen, P. S., Study, F. T. A. D. C., Study, A. D. C., Mintzer, J., Reynolds, B. A., Karlawish, J., Galasko, D., Heidebrink, J., Aggarwal, N., Graff-Radford, N., . . . Alexopoulis, G. (2015). A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000002035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.